Blph stock zacks
Analysts Set $36.24 Price Target for Bellerophon ... Mar 20, 2020 Price Target Analysis of Bellerophon Therapeutics, Inc ... Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) belonging to the Medical sector has surged 16.45% and closed its last trading session at $0.63. The company reported its EPS on 11/08/2016. Currently, the stock has a 1 Year Price Target of $12. The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Bellerophon Therapeutics Inc. (Nasdaq: BLPH) :: LD Micro Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® … Bellerophon Therapeutics Market Cap 2013-2019 | BLPH ...
BLPH - Bellerophon Ther Com Stock Price - Barchart.com
Date Headline; Is Bellerophon Therapeutics, Inc. (BLPH) A Good Stock To Buy? finance.yahoo.com - June 4 at 7:31 PM: Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares Bellerophon Therapeutics. BLPH 12.87 0.08 (0.63%). NASDAQ Updated Jun 8, 2020 8:39 PM
Bellerophon Therapeutics Inc BLPH - Quotes, Financials ...
BLPH Bellerophon Therapeutics, Inc. Stock Quote BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow Zacks Small Cap Research-15.89% Oct-23-19 08:30AM Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019
Analyst Information for Bellerophon ... - Stock Market Today
Zacks Small-Cap Research Zacks Investment Research Page 2 scr.zacks.com SNAPSHOT Bellerophon Therapeutics, Inc. (BLPH) is a clinical development-stage medical therapeutics company focused on the development and commercialization of a novel nitric oxide therapy which, if successfully fully developed and BLPH: More Clinical Data Supports Utility of INOpulse ...
IB does not accept short sale orders for US stocks that are not eligible for DTC BLPH, USD, BELLEROPHON THERAPEUTICS INC, Log In to Check Availability CZA, USD, INVESCO ZACKS MID-CAP ETF, Log In to Check Availability.
BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow Zacks Small Cap Research-15.89% Oct-23-19 08:30AM Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Analyst Information for Bellerophon ... - Stock Market Today Consensus Rating for BLPH is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. Ratings are a translation of brokers' recommendations to the recommendation scale, which ranges from a rating of 1 (a strong buy) to a rating of 5 (a strong sell). Analysts Set $36.24 Price Target for Bellerophon ... Mar 20, 2020 Price Target Analysis of Bellerophon Therapeutics, Inc ... Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) belonging to the Medical sector has surged 16.45% and closed its last trading session at $0.63. The company reported its EPS on 11/08/2016. Currently, the stock has a 1 Year Price Target of $12. The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a